hi Fluffy, smallcap Senetek (sntky/888791) füllt sich langsam mit viel Substanz:

Beiträge: 2
Zugriffe: 155 / Heute: 1
hi Fluffy, smallcap Senetek (sntky/888791) füllt sich langsam mit viel Substanz: storyhunter
storyhunter:

hi Fluffy, smallcap Senetek (sntky/888791) füllt sich langsam mit vi.

 
15.06.00 14:52
#1
Nach der Meldung Koperation mit The Beauty Shop jetzt Kooperation mit Revlon:



Revlon and Senetek Enter Licensing Agreement Revlon to Introduce Kinetin-Based Skincare and Cosmetic Products to Mass Market  
       THURSDAY, JUNE 15, 2000 7:22 AM
- PRNewswire

NAPA, Calif. and NEW YORK, Jun 15, 2000 /PRNewswire via COMTEX/ -- Revlon, Inc. (NYSE:REV) and Senetek PLC (Nasdaq:SNTKY) today announced that they have entered into an exclusive licensing agreement which provides Revlon with Senetek's patented Kinetin skincare technology for use in creating skin care and cosmetic products. Terms of the agreement grant Revlon exclusive worldwide rights for Kinetin in the mass market, excluding parts of Asia. In exchange for exclusivity, Senetek has received a nonrefundable licensing fee of $3 million. The contract provides for royalty payments to Senetek subject to annual minimums.

Kinetin (N6-furfuryladenine) is an essential plant growth factor that retards senescence of plants and was shown to delay age-related changes in cultured human skin cells in clinical testing at the University of California, Irvine. It is currently an ingredient in dermatologist dispensed and recommended skincare products.

Frank Massino, Chairman and Chief Executive Officer of Senetek, stated, "With Revlon's well-established distribution network, extensive portfolio of brands and dynamic new leadership and management team, we are confident that the substantial potential of Kinetin will be realized in the global skincare market."

Jeffrey M. Nugent, President and Chief Executive Officer of Revlon, Inc., said, "This agreement will both enhance our ability to create innovative products and accelerate the achievement of our strategic goal of making skin care a much more significant part of our overall business."

Revlon, Inc. is a worldwide cosmetics, skin care, fragrance, and personal care products company. The Company's vision is to become the world's most dynamic leader in global beauty and skin care. Revlon brands include Revlon(R), Almay(R), Ultima II(R), Charlie(R), and Flex(R), sold in approximately 175 countries and territories. www.revlon.com.

Senetek PLC is a science-driven biopharmaceutical company engaged in the development of products for dermatological therapeutics and the treatment of male and female sexual dysfunction. www.senetekplc.com.

The Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking statements that involve risks and uncertainties including the risks detailed from time to time in the Company's Securities and Exchange Commission filings.

CONTACT: Richard Woods, 212-527-5791, or investors, Laura Kiernan, 212-527-5230, both for Revlon, Inc.; or Press and Investor Relations of Senetek PLC, 707-226-3900, ext. 102, or ir@senetek.net.

SOURCE Revlon, Inc.; Senetek PLC

CONTACT:          Richard Woods, 212-527-5791, or investors, Laura Kiernan,
                 212-527-5230, both for Revlon, Inc.; or Press and Investor Relations of
                 Senetek PLC, 707-226-3900, ext. 102, or ir@senetek.net
                 /Company News On-Call:  www.prnewswire.com/comp/115015.html or fax,
                 800-758-5804, ext. 115015

URL:              www.revlon.com
                 www.senetekplc.com
www.prnewswire.com

(C) 2000 PR Newswire. All rights reserved.


SOLLTE Analyst HEIKO THIEME MIT SEINEM KURSZIEL VON 10$ RECHT BEHALTEN????
ach wär das schön....
gruß storyhunter
hi Fluffy, smallcap Senetek (sntky/888791) füllt sich langsam mit viel Substanz: storyhunter

Senetek (sntky/888791) , weiter gehts mit vorl. FDA-Zulassung für .

 
#2
Die Spritze ist besser als Viagra, keine bösen Nebenwirkungen!!!
Senetek wird langsam den Weg machen.
p.s. Oben muß es heißen 'The Body Shop' und nicht 'The Beauty Shop....


Quelle: marketwatch.com:
Senetek (SNTKY: news, msgs) shares closed up 13 percent after the FDA upgraded the status of erectile dysfunction drug Invicorp IND to a partial clinical hold, allowing human studies in the U.S.

The London-based company made the announcement just before the closing bell. Shares closed up 9/32 to 2 3/8.

The human studies have a limited three-month duration, with total number of doses not exceeding three per week.

The FDA also recommended a two-year rodent study of Invicorp.

Also, the New Zealand Medicines and Medical Devices Safety Authority granted the drug full approval.


HIER DIE VOLLSTÄNDIGE MELDUNG DAZU:

FDA Upgrades Invicorp(TM) Status to Partial Clinical Hold Senetek Announces Full Approval In New Zealand  
       MONDAY, JULY 03, 2000 12:43 PM
- PRNewswire

NAPA, Calif., Jul 3, 2000 /PRNewswire via COMTEX/ -- Senetek PLC (Nasdaq:SNTKY) announced today that the U.S. Food and Drug Administration (FDA) has upgraded the status of the Invicorp(TM) IND to a partial clinical hold, allowing human studies to be conducted in the U.S. with a limited duration of three months and total number of doses not exceeding three per week. The FDA also recommended that the Company conduct a two-year rodent study of Invicorp(TM) as a result of previously reported brown adipose tissue proliferations observed in the course of a competitor's rodent study in which phentolamine mesylate, an ingredient formulated in low concentrations in Senetek's Invicorp(TM) product, was administered daily.

Senetek further announced that the New Zealand Medicines and Medical Devices Safety Authority has granted full approval for Invicorp(TM) for the treatment of Erectile Dysfunction (ED). Invicorp(TM) has been fully approved for use in Denmark since 1998 and is conditionally approved in the United Kingdom where it is currently available on a compassionate-use basis. The Committee on Safety of Medicines will meet in the U.K. in late July to review data provided by Senetek regarding the conditional approval and a response from the Medicines Control Agency is expected in August of this year. Senetek is seeking pan-European approval for Invicorp(TM) under the Mutual Recognition Process using Denmark as the reference member state.

Invicorp(TM) is a combination of vasoactive intestinal peptide (VIP) with 1 to 2 mg of phentolamine mesylate (PMS). This combination has shown excellent results in a wide range of patients, many having failed on other therapies for the treatment of ED. In completed Phase III clinical trials conducted in the United Kingdom, Denmark, Ireland and Australia, Invicorp(TM) demonstrated an efficacy level of 83% without serious side effects. The most frequently reported side effect was transient facial flushing, which typically subsided within minutes after use.

Unlike many other ED therapies, Invicorp(TM) has no known contraindications. Other significant advantages over existing therapies include: rapid onset of erection after stimulation -- typically within 2-5 minutes; the ability to induce an erection up to 2 1/2 hours after administration with natural termination of an erection after ejaculation, and efficacy in the treatment of organic Erectile Dysfunction. Invicorp(TM) is administered using a novel drug delivery system that renders the self-injection process uncomplicated and pain free.

Invicorp(TM) is currently prescribed on a named patient basis in the United Kingdom. It is estimated that more than 64,000 injections of Invicorp(TM) have been successfully administered by patients in the UK under this program.

Other products in Senetek's pipeline of treatments for sexual dysfunction include 17 patented novel compounds for the topical treatment of male and female sexual dysfunction. One of these compounds, Stearyl-Norleucine-VIP (SNV) has completed animal testing with no toxicity indications and is ready to enter Phase I clinical trials.

Senetek PLC is a science-driven biopharmaceutical company engaged in the development of products for dermatological therapeutics and the treatment of sexual dysfunction. www.senetekplc.com.

The Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking statements that involve risks and uncertainties including the risks detailed from time to time in the Company's Securities and Exchange Commission filings.

   Contact:
   Investor Relations
   707-226-3900 x102
   ir@senetek.net

SOURCE Senetek PLC
CONTACT:          Investor Relations of Senetek PLC, 707-226-3900, ext. 102, or
                 ir@senetek.net
                 /Company News On-Call:  www.prnewswire.com/comp/115015.html or fax,
                 800-758-5804, ext. 115015

URL:              www.senetekplc.com
www.prnewswire.com

ICH HALTE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!10$!!!!!!!!!!!!!!!!!!!­
so long
sh


Börsenforum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen